Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Ophthalmology

Dual VEGF receptor antagonist reverses retinal disease

Nature Reviews Drug Discovery volume 14, page 820 (2015)Cite this article

Subjects

Pathological angiogenesis is involved in several severe retinal disorders, including age-related macular degeneration (AMD). Although antibodies targeting the pro-angiogenic factor VEGF have been used to successfully treat AMD, not all patients respond and treatment requires intravitral injection. Now, Sidman et al. report that a small cyclic retro-inverted peptidomimetic named Vasotide, which selectively binds to the VEGF receptors VEGFR1 and neuropilin 1, decreases pathological retinal angiogenesis when administered as eye drops to mouse and monkey retinal disease models.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sidman, R. L. et al. The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease. Sci. Transl. Med. 7, 309ra165 (2015)

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Authors
  1. Sarah Crunkhorn
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crunkhorn, S. Dual VEGF receptor antagonist reverses retinal disease. Nat Rev Drug Discov 14, 820 (2015). https://doi.org/10.1038/nrd4801

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrd4801

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research